KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolent Health (EVH) EBITDA (2016 - 2025)

Historic EBITDA for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to -$27.6 million.

  • Evolent Health's EBITDA rose 1166.34% to -$27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$181.9 million, marking a year-over-year decrease of 7433.48%. This contributed to the annual value of -$94.0 million for FY2024, which is 3399.56% up from last year.
  • As of Q3 2025, Evolent Health's EBITDA stood at -$27.6 million, which was up 1166.34% from -$51.1 million recorded in Q2 2025.
  • In the past 5 years, Evolent Health's EBITDA ranged from a high of $1.9 million in Q3 2022 and a low of -$72.2 million during Q1 2025
  • Moreover, its 5-year median value for EBITDA was -$25.3 million (2024), whereas its average is -$23.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 11427.59% in 2022, then tumbled by 189188.61% in 2023.
  • Evolent Health's EBITDA (Quarter) stood at -$5.6 million in 2021, then plummeted by 103.38% to -$11.5 million in 2022, then plummeted by 260.42% to -$41.4 million in 2023, then grew by 25.09% to -$31.0 million in 2024, then grew by 10.97% to -$27.6 million in 2025.
  • Its last three reported values are -$27.6 million in Q3 2025, -$51.1 million for Q2 2025, and -$72.2 million during Q1 2025.